Quantcast
Home > Quotes > HSGX

Histogenics Corporation Common Stock (HSGX) Quote & Summary Data

HSGX 
$2.81
*  
0.08
2.77%
Get HSGX Alerts
*Delayed - data as of Jun. 22, 2018  -  Find a broker to begin trading HSGX now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
6
Today's High / Low
$ 2.85 / $ 2.76
Share Volume
77,534
50 Day Avg. Daily Volume
82,453
Previous Close
$ 2.89
52 Week High / Low
$ 3.35 / $ 1.60
Market Cap
80,611,628
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.23

Intraday Chart

Shares Traded

Share Volume:
77,534
50 Day Avg. Daily Volume:
82,453

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.26

Trading Range

The current last sale of $2.81 is 75.63% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.85 $ 3.35
 Low: $ 2.76 $ 1.60

Company Description (as filed with the SEC)

We are a leader in the development of restorative cell therapies (RCTs). We use the term RCT to refer to a new class of products we are developing that are designed to offer patients rapid-onset pain relief and restored function through the repair of damaged or worn tissue. Our lead investigational product, NeoCartĀ®, is an innovative cell therapy that utilizes various aspects of our RCT platform to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. NeoCart is designed to rebuild a patient's own knee cartilage to treat pain at the source, improve function and potentially prevent a patient's progression to osteoarthritis (OA). We have designed NeoCart to perform like articular hyaline cartilage at the time of treatment with the objective of providing patients with an accelerated recovery as compared to other alternatives, including microfracture, the current standard of care used to treat knee cartilage damage.  ... More ...  

Risk Grade

Where does HSGX fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.88
Open Date:
Jun. 22, 2018
Close Price:
$ 2.81
Close Date:
Jun. 22, 2018

Consensus Recommendation

Analyst Info